Summary: Evaluated valsartan versus placebo in patients with New York Heart Association (NYHA) functional class II-IV heart failure and EF < 40%. The primary endpoint of all-cause mortality was significantly reduced by valsartan. There was no benefit if valsartan was added to an ACE inhibitor and in fact mortality was increased in this setting. Symptoms of heart failure were improved with valsartan.
N Engl J Med. 2001 Dec 6;345(23):1667-75.
Eponym: Valsartan in Heart Failure Trial